# Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

> **NCT03934216** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 131 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** BMS-986165
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03934216
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2021-06-13
- **Final completion:** 2023-04-04
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03934216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03934216, "Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03934216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*